Bio Fire Diagnostics products

Pneumonia patients are frequently over-treated with antibiotics because it is difficult to quickly identify the pathogen responsible for their symptoms. The BioFire Pneumonia Panel delivers fast, accurate pathogen identification in about one hour, which may allow physicians to put patients on appropriate therapy quicker.

With overlapping symptoms, distinguishing possible causes of gastroenteritis can be challenging for any clinician. To further complicate diagnosis, traditional testing methods are slow, labor intensive, and fail to reveal the etiology of a patient’s gastrointestinal symptoms.¹ Fortunately, syndromic testing from the BioFire GI Panel eliminates limitations from conventional methods by providing, faster, more accurate, and comprehensive results.

The BioFire RP EZ uses a molecular syndromic approach to accurately detect and identify a wide range of pathogens—not just Flu A and Flu B. As a healthcare provider, this means your patients can receive the right treatment the first time, potentially leading to higher patient satisfaction and lower costs. And as the name implies, it’s easy and can be performed right in your office or clinic.¹

SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

Early identification and treatment of sepsis are essential to combat one of the leading causes of hospital patient deaths.¹ With 43 targets, the newly expanded and FDA-cleared BioFire^® Blood Culture Identification 2 (BCID2) Panel detects pathogens and antimicrobial resistance genes directly from positive blood cultures.